4th Quarter - Report

ABBVIE, INC. for ABBVIE INC.

Firm
Client
Income
—
Expenses
$600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

A variety of international trade issues (TPA, TTIP, TPP)

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CATHERINE DRATZ FERGUSON —
ANDREW KAPLAN —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Health Issues HCR

Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Reconciliation Act of 2010; BPCIA (biosimilars); S. 621, Safe Prescribing Act of 2013; H. R. 1285, A bill to amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug; H.R. 3204, Drug Quality & Security Act of 2013; S. 957, Drug Supply Chain Security Act; H.R. 3723, Viral Hepatitis Testing Act of 2013; Proposals to improve viral hepatitis screening and testing;Discussions to clarify or reform the 340B program

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CATHERINE DRATZ FERGUSON —
JOHN P. FORD —
ANDREW KAPLAN —
HEATHER STRAWN —
ADELE R WITENSTEIN —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Bills named: S. 957 (113th), H.R. 1285 (113th), H.R. 3723 (113th), S. 621 (113th), H.R. 3204 (113th)

Medicare/Medicaid MMM

Policies to enhance patient access to medicines in Medicare; Medicare payment proposals, S. 117 / H.R. 1102, Medicare Prescription Drug Price Negotiation Act of 2013; S. 740 / H.R. 1588, Medicare Drug Savings Act of 2013; H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
JOHN P. FORD —
ANDREW KAPLAN —
HEATHER STRAWN —
ADELE R WITENSTEIN —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Bills named: S. 117 (113th), S. 740 (113th), H.R. 1102 (113th), H.R. 1588 (113th), H.R. 2925 (113th)

Budget/Appropriations BUD

H.R. 2725, Food & Drug Administration Safety Over Sequestration Act of 2013; S. 1413, FDA User Fee Protection Act of 2013

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
JOHN P. FORD —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Bills named: H.R. 2725 (113th), S. 1413 (113th)

Taxation/Internal Revenue Code TAX

Proposals to reform domestic and international tax structures (no bills introduced)

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
CATHERINE DRATZ FERGUSON —
JOHN P. FORD —
ANDREW KAPLAN —
HEATHER STRAWN —
ADELE R WITENSTEIN —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Copyright/Patent/Trademark CPT

S. 1720, Patent Transparency and Improvements Act of 2013; H.R. 3309, Innovation Act; S. 214, Preserve Access to Affordable Generics Act of 2013; H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013

LobbyistCovered position, as disclosed
JOHN P. FORD —
ANDREW KAPLAN —
HEATHER STRAWN —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3309 (113th), S. 214 (113th), H.R. 3709 (113th), S. 1720 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.